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The Runt box domain DNA‑binding transcription factors (RUNX) play key roles in 
hematopoietic, bone, and gastric development. These factors regulate angiogenesis 
and tumorigenic events, functioning as either activators or repressors of target genes. 
Although RUNX2 is an essential bone maturation factor, it has also been found to promote 
transformation in vivo and cell proliferation in vitro, perhaps by associating with specific 
coactivators or corepressors. Adenoviral‑mediated overexpression of dominant negative 
RUNX2 or specific reduction of RUNX2 with RNA‑interference inhibits cell proliferation. 
To determine whether RUNX2 also plays a role in cell transformation, RUNX2 interactions 
with the coactivator Yes‑associated protein (YAP65) were examined. RUNX2 associated 
with YAP65 via a proline‑rich segment in the C‑terminal domain (PPPY) and coexpression 
of RUNX2 and YAP65 significantly increased foci formation and anchorage‑independent 
growth relative to each factor alone. However, in contrast to wild‑type RUNX2, a mutant 
RUNX2(P409A), which does not bind YAP65, did not cooperate with YAP65 to promote 
anchorage‑independent growth. RUNX2 is a strong repressor of the cyclin‑dependent 
kinase inhibitor p21CIP1, which is known to mediate cell transformation. Overexpression 
of YAP65 prevented RUNX2‑dependent downregulation of p21CIP1 protein expression 
while promoting cell transformation. The RUNX2(P409A) mutant retained the ability 
to bind DNA and repress the p21CIP1 promoter as shown by DNA precipitation and 
luciferase‑reporter assays, respectively, but was not able to relieve repression of the 
p21CIP1 promoter. Therefore, these results reveal a novel function of the RUNX2 and 
YAP65 interaction in oncogenic transformation that may be mediated by modulation of 
p21CIP1 protein expression.
IntRoductIon
The	RUNX	 family	 of	 transcription	 factors	 is	 composed	 of	 three	 homologous	 genes	
(RUNX1,	 RUNX2,	 and	 RUNX3)	 each	 containing	 a	 conserved	 Runt	 DNA	 binding	
domain.	The	 RUNX	 proteins	 are	 critical	 for	 regulation	 of	 mammalian	 developmental	
events	 related	 to	 hematopoiesis	 (RUNX1),1	 osteogenesis	 (RUNX2)2	 or	 epithelial	 cell	
maturation	 (RUNX3).3	 Although	 RUNX1	 has	 been	 implicated	 in	 certain	 human	
leukemias	 due	 to	 translocation	 events	 and	 mutations,	 and	 silencing	 of	 the	 RUNX3	
promoter	 is	 a	 causal	 event	 in	 gastric	 carcinomas,	 the	 role	 of	RUNX2	 in	 tumorigenesis	
is	 less	 characterized.	The	 Runx2	 gene	 is	 a	 common	 target	 for	 retroviral	 insertion	 and	
overexpression	resulting	 in	T-cell	 lymphomas.4	Overexpression	of	the	RUNX2	gene	has	
been	 linked	 to	T-cell	oncogenesis	 since	RUNX2	transgenic	mice	developed	 lymphomas	
in	combination	with	c-myc	or	Pim1,	or	 in	the	absence	of	p53.4-6	Recently,	Runx2	was	
shown	 to	 collaborate	 with	MYC	 in	 lymphoma	 development	 by	 suppressing	 apoptotic	




and	 breast	 cancer	 cells	 preferentially	 metastasize	 to	 the	 bone,10	 RUNX2	may	 play	 an	
important	 role	 in	 breast	 cancer	 tumorigenesis.	 RUNX2	mRNA	 and	 protein	 were	 also	




RUNX2	 is	 a	 strong	 transcriptional	 activator	 or	 repressor	 of	 target	 genes	 depending	



















deacetylases,	 and	 the	 TLE1/Groucho	 factor,	 do	 not	 bind	 DNA,	
but	 are	 RUNX2-associating	 proteins	 that	 inhibit	 transactiva-
tion.15-17	 Coactivator	 proteins	 such	 as	 p300/CBP	 and	 CBFb	 also	
do	not	bind	to	DNA,	but	associate	with	RUNX2	to	mediate	trans-	
activation.18-22	 One	 such	 coactivator,	 the	 Yes-associated	 protein,	
YAP65,	is	a	phosphoprotein	that	interacts	with	the	proto-oncogene	
c-yes,	 a	 nonreceptor	 tyrosine	 kinase	 of	 the	 Src	 family.	 YAP65	
contains	two	SH3	domains,	a	PDZ	domain,	and	a	WW	domain,23	
all	of	which	mediate	specific	protein	interactions.	The	WW	domain	
of	 YAP65	 consists	 of	 three	 anti-parallel	 b	 strands	 forming	 a	
hydrophobic	 pocket	 that	 binds	 proline	 containing	 motifs	 such	 as	
the	 peptide	 ligand	 motif	 PPxY.24,25	 It	 has	 been	 determined	 that	
the	WW	domain	of	YAP65	binds	the	sequence	PPPY	in	RUNX126	
and	RUNX2,27	and	may	interact	with	RUNX3	because	of	identical	
PPPY	 motifs	 in	 these	 RUNX	 family	 members.	 Upon	 phosphory-
lation,	YAP65	is	sequestered	in	the	cytoplasm	by	14-3-3.	However,	
when	 YAP65	 is	 unphosphorylated,	 it	 is	 localized	 to	 the	 nucleus	
where	it	can	interact	with	transcription	factors.	YAP65	is	known	to	
be	 a	 strong	 coactivator	 of	 the	TEAD/TEF	 family	 of	 transcription	
factors28	 and	p73.29,30	However,	 the	 functional	 significance	 of	 the	
RUNX-YAP65	interaction	has	not	been	elucidated.
We	 showed	 previously	 that	 ectopic	 expression	 of	 RUNX2	
prevents	 TGFb-mediated	 inhibition	 of	 cell	 growth.31	 RUNX2	
DNA-binding	activity,	cell	cycle	progression,	pRb	phosphorylation,	
and	DNA	synthesis	correlated	with	cell	proliferation.	RUNX2	also	
repressed	 p21CIP1	 promoter	 activity	 and	 reduced	 p21CIP1	 protein	
levels.	 RUNX2	 modulation	 of	 p21Cip1	 expression	 and	 promotion	
of	EC	proliferation	suggested	that	RUNX2	might	promote	cellular	
transformation.	 Recently,	 we	 reported	 that	 shRNA-mediated	
downregulation	 of	 RUNX2	 inhibited	 cell	 proliferation	 and	 that	
RUNX2	overexpression	increased	3T3	fibroblast	growth	in	soft	agar,	
a	 transforming	activity	mediated,	 in	part,	 through	cdk1-dependent	
phosphorylation	 of	 RUNX2.32	 Further,	 adenoviral-mediated	 over-
expression	of	a	dominant	negative	factor,	which	inhibits	endogenous	
RUNX2,	inhibited	EC	proliferation.	We	now	identify	the	transcrip-
tional	 coactivator,	 YAP65,	 as	 a	 synergistic	 factor	 that	 cooperates	
with	 RUNX2	 to	 increase	 cell	 transformation.	 RUNX2	 promoted	
transcriptional	repression	of	the	cdk	inhibitor	p21CIP1,	while	YAP65	





interaction	and	 reveal,	 for	 the	 first	 time,	 that	p21CIP1	regulation	 is	
one	possible	mechanism	for	this	transforming	activity.
MAtERIAls And MEthods
Cell culture and reagents.	Human	bone	marrow	endothelial	cells	
(HBME),	HEK293,	 293T,	 and	NIH3T3	 fibroblasts	were	 cultured	
in	 DMEM	 (Biofluids)	 and	 10%	 FBS	 (Biofluids)	 and	 used	 until	
passage	 20.	 Stable	 NIH3T3	 cell	 lines	 were	 selected	 in	 1	 mg/ml	
G418	(Invitrogen)	and	only	used	for	three	more	passages	after	selec-
tion.	 HCT116.p21-/-	 and	 parental	 cells	 were	 cultured	 in	McCoy’s	
medium	 containing	 10%	FBS.	Monoclonal	 anti-flag	M2	 antibody	
(Sigma)	 was	 used	 to	 detect	 or	 immunoprecipitate	 the	 flag-tagged	
RUNX2	 or	 RUNX2(P409A)	 mutant	 proteins.	 Monoclonal	
HA.11	 antibody	 (Covance)	 was	 used	 to	 detect	 or	 immunopre-
cipitate	the	HA-tagged	YAP65.	Anti-p21CIP1,	anti-cdk4,	anti-PCNA	
and	 anti-actin	 antibodies	 were	 obtained	 from	 Santa	 Cruz,	 Inc.	
(Santa	 Cruz,	 CA).	 Anti-RUNX2	 antibody	 (AML3	 Ab)	 was	 from	
Oncogene	Research	Products	(Cambridge,	MA).
Plasmids.	 pCMV-tag2a	 (NEO)	was	purchased	 from	Stratagene.	
The	full	length	RUNX2	cDNA	was	inserted	into	the	BamH1/Xho1	
sites	of	the	pCMV-tag2a	as	previously	described.31	Flag-tag	RUNX2	
or	 flag-tag	 RUNX2DN	 (dominant	 negative;	 missing	 exon8)	 was	
subcloned	 into	 the	 pShuttle	 vector	 (Clontech)	 before	 restriction	
enzyme	cloning	into	the	Adeno-X	adenoviral	vector	(BD	Biosciences,	
Palo	 Alto,	 CA).	 The	 dominant	 negative	 activity	 of	 RUNX2DN	
was	 previously	 quantified	 using	 p21CIP1	 promoter-luciferase	
assays.31	Adenoviruses	were	prepared	in	HEK293	packaging	cells	by	
sequential	 transfection/infection	 and	 viral	 titers	 of	 HEK293	
supernatants	were	determined	by	cell	 lysis	 as	 recommended	by	 the	
manufacturer	 (BD	Biosciences).	The	YAP65	 expression	 vector	 and	
the	 empty	 vector	 control	 (XJ540-HA)	 were	 gifts	 from	 Dr.	 Iain	
Farrance	 (University	 of	 Maryland,	 Baltimore,	 MD).	 The	 p21CIP1	
promoter	luciferase	plasmid	(WWP-LUC)	was	a	gift	from	Dr.	Bert	
Vogelstein	 (Johns	 Hopkins	 University,	 Baltimore,	 MD).	 Using	 a	
site-directed	 mutanagesis	 kit	 (Invitrogen),	 a	 point	 mutation	 was	
introduced	 into	 the	RUNX2	cDNA,	which	changed	the	proline	at	
position	409	 to	an	alanine,	 to	create	 the	RUNX2(P409A)	mutant.	
The	mutation	was	verified	by	sequencing.
Immunoprecipitation and western blot analysis.	 Nuclear	
proteins	were	isolated	using	NucBuster	(Novagen).	Protein	concen-
tration	was	determined	with	the	Bio-Rad	Protein	Assay.	One	mg	of	
protein	 was	 diluted	 into	 500	 ml	 of	 immunoprecipitation	 (IP)	
buffer	 [20	mM	Tris,	pH	7.5,	2	mM	CaCl2,	1%	Triton	X-100	and	
1X	protease	inhibitor	cocktail	(Roche)]	and	was	precleared	with	30	ml	
of	 protein	 G	 sepharose.	 For	 immunoprecipitations,	 1	 mg	 of	
antibody	 (M2	or	HA)	pre-bound	 to	30	ml	 of	Protein	G	 sepharose	
was	 combined	 with	 Protein	 G	 precleared	 nuclear	 extracts	 and	
incubated	on	an	orbital	shaker	for	at	least	12	hr	at	4˚C.	The	mixture	
was	 centrifuged,	 and	 the	 pellet	 was	 washed	 three	 times	 with	 the	
IP	 buffer.	 All	 excess	 fluid	was	 removed	 and	 2.5	ml	 reducing	 agent	
(Invitrogen)	 and	 22.5	 ml	 of	 4x	 Laemmli	 buffer	 were	 added	 to	
the	 pellet.	 Samples	 were	 boiled	 for	 10	 min	 and	 centrifuged.	The	
supernatant	 was	 loaded	 on	 a	 4–12%	 Nu-PAGE	 gel	 (Invitrogen),	
and	 electrotransferred	 to	 PVDF	 membranes	 (Invitrogen).	 The	
blots	 were	 incubated	 with	 either	 anti-M2	 antibody	 (1:1000)	 or	
anti-HA	 antibody	 (1:5000)	 followed	 by	 horseradish	 peroxidase-	
conjugated	 goat	 anti-mouse	 IgG	 (KPL,	 Gaithersburg,	 MD).	 All	
other	 antibodies	were	used	 at	 concentrations	 recommended	by	 the	
manufacturer	(Santa	Cruz,	Inc.,	Santa	Cruz,	CA).	Specific	proteins	
were	 detected	 by	 enhanced	 chemiluminescence	 (ECL,	 Amersham	
Pharmcia	Biotech,	Buckinghamshire,	England).
DNA precipitation assays.	 Two	 single	 stranded,	 biotin	
labeled	 oligonucleotides	 corresponding	 to	 RUNX	 binding	 site	
A	 in	 the	 distal	 p21CIP1	 promoter	 were	 hybridized	 to	 generate	 a	
double-stranded	probe.	For	the	wild-type	probe	(Runx2	binding	site	
in	 bold),	 the	 specific	 oligonucleotides	 used	were	 5'GCTCAGTAC
CACAAAAATTC-biotin	 3'	 (sense)	 and	 5'GAATTTTTGTGGTA
CTGAGC-biotin	3'	(antisense).	For	the	mutant	probe,	 the	specific	
oligonucleotides	 used	 were	 5'GCTCAGTCGAACAAAAATTC-	
biotin	 3'	 (sense)	 and	 5'GAATTTTTGTTCGACTGAGC-biotin	
3'	 (antisense).	 Equal	 concentrations	 of	 sense	 oligo	 and	 antisense	
oligo	 were	 added	 in	 annealing	 buffer	 for	 a	 final	 concentration	 of	
3.33	mM	of	double-stranded	oligo	 in	0.1	M	Tris,	pH	7.6,	0.01	M	
























beads	 (Pierce).	 The	 biotinylated,	 double	 stranded	 DNA	 probe	
(10	ml	of	a	3.33	mM	stock)	and	10	mg	of	poly	dI/dC	were	added	to	
the	 supernatant	 and	 incubated	 at	 4˚C	 overnight.	To	 the	 mixture,	
30	 ml	 of	 the	 streptavidin	 beads	 were	 added	 and	 the	 incubation	
continued	 at	 4˚C	 for	 at	 least	 1	 hr.	 The	 supernatants	 were	 then	
removed	and	the	beads	were	washed	three	times	with	0.5	ml	of	the	
DNA	precipitation	buffer.	Laemmli	buffer	plus	reducing	agent	were	





were	 allowed	 to	 recover	 for	 24	 hr	 and	 then	 transfected	 with	 the	
indicated	 combination	 of	 plasmids.	 For	 all	 luciferase	 assays,	 the	
WWP-LUC	plasmid	was	used	 at	 a	 concentration	of	1	mg	per	well	
and	the	pTK-renilla	was	used	at	a	concentration	of	50	ng	per	well.	




Cell proliferation, soft agar assays and foci formation.	HBME	
or	 3T3	 fibroblasts	 were	 transfected	 with	 the	Mirus	 LT1	 transfec-
tion	reagent	(Mirus	Corporation)	as	described	previously.31	HBME	
cells	 were	 infected	 with	 dilutions	 of	 HEK293	 viral	 supernatants	
corresponding	 to	 equivalent	 viral	 titers	 for	24	hours	 and	harvested	
and	 replated	 in	 24-well	 plates	 for	 proliferation	 assays.	 Cells	 were	
photographed	 after	 1,	 2,	 3	 and	 4	 days	 and	 cell	 numbers	 in	 each	
representative	field	were	counted.	For	growth	in	soft	agar,	DMEM,	
10%	FBS,	and	agar	(0.5%)	mixture	(2	ml)	were	added	and	allowed	
to	cool	 and	 solidify	 at	25˚C	 for	 at	 least	30	min.	Cells	 (20,000)	 in	
0.5	ml	DMEM,	10%	FBS,	and	agar	(0.33%)	were	carefully	overlaid	
on	 the	 solidified	 agar	 base	 in	 each	well.	This	mixture	was	 allowed	
to	solidify	at	25˚C	for	30	min.	The	plates	were	then	incubated	for	
ten	days	in	a	37˚C,	5%	CO2.	Colony	formation	was	compared	and	
photos	 of	 representative	 regions	 from	 each	 well	 were	 taken	 using	
a	 Zeiss	microscope,	 and	 video	 camera,	 and	 images	were	 processed	
with	Oncor	Image	software.	Each	photo	contains	multiple	computer	
images	 fitted	 together	 to	 give	 a	 larger	 representative	 view	 of	 the	
colonies	in	each	well.	For	measurement	of	foci	formation,	NIH3T3	
cells	and	transfectants	were	cultured	in	100	mm	dishes	and	allowed	




determinations.	 Significance	 was	 calculated	 using	 paired	 analysis	
(Excel	Office	Suite)	and	expressed	as	p	values.
REsults
RUNX2 promotes cell proliferation. We	showed	previously	that	
RUNX2	 protein	 expression	 and	 DNA-binding	 activity	 correlated	
with	 EC	 proliferation.31,33	 Human	 bone	 marrow	 EC	 (HBME)	
expressed	 RUNX2	 when	 subconfluent	 (proliferating),	 but	 not	 at	
confluence	 (growth	 arrested).	We	 further	 showed	 that	 overexpres-
sion	 of	 RUNX2	 in	 bovine	 aortic	 EC	 (BAEC),	 stimulated	 cell	






were	 used	 as	 controls	 during	 the	 4-day	 period.	 RUNX2	 increased	
HBME	proliferation	relative	to	controls	by	2.8-fold	(day	1),	2.5-fold	
(day	2)	and	1.8-fold	 (day	4),	while	proliferation	 in	cells	expressing	
DN	RUNX2	was	 inhibited	 by	 50%	 on	 day	 4	 (Fig.	 1).	 In	 similar	
experiments,	HBME	cells	were	also	infected	with	adenoviral	vector	
encoding	 a	 control	 green	 fluorescent	 protein	 (GFP).	 The	 growth	





by	 specific	 RNA	 interference	 inhibited	 EC	 proliferation	 and	 cell	
cycle	progression.32




showed	 that	 the	WW	domain	 of	YAP65	binds	 to	 the	PPxY	motif	
(PPPYP)	of	RUNX126	and	RUNX2.27	To	verify	a	direct	interaction	




nuclear	 fractions.	 Immunoprecipitation	 (IP)	 assays	were	performed	
with	nuclear	lysates	using	either	a	Flag.Tag	or	HA.Tag	antibody	and	
the	 proteins	 were	 detected	 by	 immunoblotting	 (Fig.	 2A).	The	 IP	
with	Flag.Tag	antibody	or	 the	 reciprocal	 IP	with	HA.Tag	antibody	
identified	 Flag.RUNX2	 and	 YAP65	 in	 the	 complexes.	 Negative	
controls	(beads	alone	or	nonspecific	IgG	coupled	to	beads)	did	not	
reveal	either	RUNX2	or	YAP65	in	the	immunoprecipitated	fractions.	
The	 immunodepleted	 lysates	 were	 analyzed	 for	 possible	 unbound	
Flag.RUNX2	 or	HA.YAP65	 by	Western	 blotting.	 Neither	 protein	
could	be	detected	 in	the	 immunodepleted	nuclear	 lysates	 (data	not	
shown).	If	YAP65	was	directly	interacting	with	RUNX2	via	the	PPxY	
motif,	a	mutation	of	the	first	proline	to	an	alanine	in	RUNX2	would	
Figure 1. RUNX2 regulates cell proliferation. Human bone marrow EC 
(HBME) were infected with adenoviral vectors expressing RUNX2 or 
dominant negative RUNX2 (RUNX2DN). After infection (days 1–4), cells were 
photographed and cell number (cells/field) was quantified. Nuclear 
proteins from HBME cells were prepared after viral infection and the 
expression of RUNX2 or RUNX2DN on day two was confirmed by Western 
blot using anti‑Flag RUNX2 antibody (inset). Results are mean ± SEM of 
triplicate samples and are representative of three separate experiments. 























with	 the	 Flag.RUNX2	 or	 Flag.RUNX2(P409A)	 and	 HA.YAP65	
showed	that	YAP65	could	associate	with	wild-type	RUNX2	but	not	
with	either	of	two	mutant	RUNX2	clones	(Fig.	2B).
RUNX2 and YAP65 synergistically increase oncogenic 
transformation.	 We	 showed	 recently	 that	 RUNX2	 promotes	
cell	 growth	 in	 soft	 agar.32	 To	 define	 the	 biological	 significance	
of	 the	 RUNX2/YAP65	 interaction,	 NIH3T3	 cells	 were	 trans-
fected	 with	 RUNX2	 or	 RUNX2	 and	 YAP65	 and	 the	 appropriate	
control	 vectors.	 Expression	 of	 RUNX2	 or	 YAP65	 was	 verified	
with	antibodies	 specific	 for	 the	Flag	or	HA-tag	
(Fig.	 3A).	 Examination	 of	 post-confluent	
cultures	 of	 transfected	 NIH3T3	 cells	 revealed	
that	 RUNX2	 or	 RUNX2	 +	YAP65-transfected	
cells	 grew	 on	 top	 of	 the	 confluent	 cell	
monolayers	 forming	 cell	 foci,	 indicative	 of	
transformation	 (Fig.	 3B).	 Freshly	 transfected	
cells	were	 prepared	 and	 suspended	 in	 soft	 agar	
to	 measure	 anchorage-independent	 growth,	
another	 indicator	 of	 transformation	 (Fig.	 3C).	
Figure 2. RUNX2 and mutant RUNX2(P409A) association with YAP65. (A) 293T 
cells were cotransfected with Flag‑Tag RUNX2 and HA‑Tag YAP65. Western blot 
analysis was performed on the cytoplasmic, C; and nuclear lysates, N. RUNX2 
localizes to the nucleus, while YAP65 is detected in the cytoplasmic and nuclear 
extracts (left panel). Nuclear lysate from the cotransfected 293T cells was either 
immunoprecipitated with the Flag‑specific antibody (RUNX2) or the HA‑specific 
antibody (YAP65) coupled to protein A‑Sepharose beads. Beads alone or beads 
coupled to isotype‑matched IgG were used as negative controls. Western blot 
analysis was performed with the immunoprecipitated proteins (right panel). 
(B) Schematic of wild‑type RUNX2 and mutant RUNX2(P409A) proteins 
(RHD, Runt Homology Domain; NLS; Nuclear Localization Sequence; NMTS, 
Nuclear Matrix Targeting Sequence). 293T cells were cotransfected with flag‑
tagged RUNX2 (lane 1), RUNX2(P409A), clone 2 (lane 2), or RUNX2(P409A), 
clone 6 (lane 3) and HA‑tagged YAP65. Input proteins are shown on the left panel. 
Nuclear lysates were immunoprecipitated with the HA‑tag antibody coupled to 
protein A‑Sepharose beads (right panel). Western blot analysis was performed with 
either Flag.RUNX2 or HA.YAP65‑specific antibodies.
Figure 3. RUNX2 and YAP65 cooperate to promote 
NIH3T3 cell transformation. (A) Western blot of NIH3T3 
cells transfected with an increasing amount of RUNX2 
or YAP65 (0 mg, 1 mg, 2.5 mg, 5 mg, 10 mg). (B) NIH3T3 
cells were transfected with control vectors (NEO and/
or HA), vectors expressing RUNX2 or YAP65, or a 
combination of RUNX2 and YAP65 (2.5 mg each). 
Foci growing above the fibroblast monolayers were 
photographed after 25 days. RUNX2 or RUNX2 
and YAP65 transfected cells continued to grow 
and form foci atop the monolayers. (C) Parental 
NIH3T3 cells transfected with control vectors (NEO 
+ HA) or vectors expressing RUNX2, RUNX2 and 
YAP65, or the mutant RUNX2(P409A) and YAP65 
were cultured in soft agar and photographed after 
14 days. (D) The number of colonies from the 
NIH3T3 cells growing in soft agar was counted. 
Colony number for each treatment was the average 
of quadruplicate wells and included five fields per 
well (n = 20). *p ≤ 0.004 for YAP65 + NEO vs. HA 
control; **p ≤ 0.0007 for RUNX2 + YAP65 vs. HA 
control; ***p ≤ 0.002 for RUNX2(P409A) + YAP65 


















After	 two	weeks	 in	 soft	 agar,	 the	RUNX2	 transfected	 cells	 formed	
five	 times	 more	 colonies	 than	 the	 NEO	 (vector	 alone)	 controls	
(Fig.	 3D).	 Moreover,	 the	 colonies	 formed	 by	 the	 combination	 of	
RUNX2	 and	 YAP65	 were	 two	 to	 five-fold	 larger	 than	 those	 of	
RUNX2	 expressing	 cells.	 The	 number	 of	 colonies	 formed	 in	 the	
presence	of	RUNX2+YAP65	was	greater	than	the	number	of	colonies	
expected	from	expression	of	RUNX2	or	YAP65	separately,	indicative	
of	 a	 synergistic	 increase	 in	 oncogenic	 transformation.	 Previous	
mutational	 analysis	 of	 the	YAP65	binding	 site	 of	RUNX1	 showed	
that	 the	 first	 two	 Pro	 and	 the	Tyr	 residues	 in	 the	YAP65	 binding	
domain	 (PPYP)	 were	 necessary	 for	 transcriptional	 activation	 of	 a	
tk-promoter	containing	a	GAL4	binding	site.26	Mutation	of	the	first	
proline	 to	 an	 alanine	 completely	 abolished	 transcriptional	 activity.	
To	 determine	 whether	 the	 increased	 cellular	 transformation	 was	
mediated	by	 the	YAP65	binding	 site	 on	RUNX2,	 cells	 transfected	
with	a	RUNX2(P409A)	vector	in	which	the	YAP65	binding	site	had	
been	mutated	 (Fig.	2B)	were	used	 in	 the	 soft	 agar	 assay	 (Fig.	3C).	




tion	 between	 RUNX2	 and	 YAP65	 is	 necessary	 to	 induce	 loss	 of	
contact	inhibition	and	growth	in	soft	agar,	established	indicators	of	
cellular	transformation.
Requirement for p21CIP protein expression in anchorage 




rubicin.31	To	 determine	 whether	 p21CIP1	 expression	 was	 involved	










culture	 (data	 not	 shown),	 as	 reported	 previously.35	Therefore,	 the	
difference	in	growth	in	soft	agar	may	be	due	to	the	ability	of	p21CIP1	







for	 p21CIP1	 protein	 by	 Western	 blotting	 (Fig.	 4B).	 As	 expected,	
RUNX2	inhibited	p21CIP1	protein	expression	in	a	dose-dependent	
manner.	 However,	 RUNX2	 did	 not	 repress	 p21CIP1	 protein	 in	
YAP65	overexpressing	cells,	consistent	with	the	enhanced	ability	of	
YAP65	 to	promote	cell	 transformation	 (Fig.	3).	From	quantitative	
densitometry,	 the	 p21CIP1/Actin	 ratios	 declined	 with	 increasing	
RUNX2	expression,	but	were	unchanged	in	the	presence	of	YAP65.	




Repression of the p21CIP promoter in response to RUNX2 and 














cells	 transfected	 with	 either	 of	 two	 mutant	 Flag.RUNX2(P409A)	
clones	were	isolated.	Both	RUNX2(P409A)	mutant	clones	retained	
DNA-binding	activity	(Fig.	5A,	c).
Ectopic	 expression	 of	 RUNX2	 is	 known	 to	 repress	 p21CIP1	
promoter	 activity	 in	 nontransformed	 NIH3T3	 cells.31	 Consistent	
with	published	results,16	Flag.RUNX2	repressed	a	p21CIP1	promoter-
luciferase	 construct	 in	 NIH3T3	 cells	 (Fig.	 5B).	 NIH3T3	 cells	
were	 also	 transfected	 with	 two	 different	 clones	 of	 the	 mutant	
RUNX2(P409A)	 and	 luciferase	 activity	 was	 measured.	 Both	
mutant	RUNX2	clones	 repressed	p21CIP1	promoter	 activity	 to	 the	
Figure 4. YAP65‑mediated regulation of p21CIP1 cdk inhibitor expression. 
(A) HCT116 (p21‑/‑) or parental cells were harvested and cultured in soft 
agar as described in Figure 3. Representative fields from triplicate wells 
were photographed and the number of colonies per well was calculated. 
Inset shows Western blot confirming reduction of p21Cip1 protein in HCT116 
(p21‑/‑) cells. (B) Expression of p21CIP1, cdk4, PCNA and actin was 
measured by Western blot with specific antibodies in cells infected with 
increasing doses of RUNX2‑expressing adenovirus as described in the 
Experimental Procedures. Cells had been previously transfected with control 
plasmid or YAP65 (1 mg/well). Western blots were scanned and density of 




















same	 extent	 as	 wild	 type	 RUNX2	
(Fig.	 5B).	 Since	 YAP65	 associates	
with	RUNX2,	we	wanted	 to	 assess	
whether	 YAP65	 could	 regulate	
repression	of	 the	p21CIP1	promoter	
by	 RUNX2.	 At	 a	 constant	 input	
(0.25	ug)	of	NEO	control	or	Flag.
RUNX2	vector,	increasing	amounts	
of	 HA.YAP65	 were	 added	 to	 each	
sample	 (Fig.	 5C).	 HA.YAP65	 in	
the	 presence	 of	 NEO	 control	 had	
no	 significant	 effect	 on	 p21CIP1	
promoter	 activity	 (Fig.	 5C,	 gray	
bars).	 Increasing	 concentrations	 of	
HA.YAP65	 alleviated	 the	 RUNX2	
repression	 of	 p21CIP1	 promoter	
activity	 in	 a	 dose	 dependent	
manner,	resulting	in	complete	relief	
of	 p21CIP1	 promoter	 repression	
at	 1.0	 ug	 DNA	 (Fig.	 5C,	 dark	
bars),	 consistent	 with	 the	 observed	
expression	 of	 p21CIP1	 protein	
(Fig.	4B).	However,	HA.YAP65	was	
unable	 to	 relieve	p21CIP1	promoter	
repression	 by	 the	 mutant	 Flag.
RUNX2(P409A)	 (Fig.	 5C,	 white	
bars).	A	YAP65	 control	 vector	 had	
no	 effect	 on	 RUNX2	 repression	
and	did	not	alleviate	 repression	of	
the	p21CIP1	promoter	by	RUNX2	
or	 RUNX2(P409A)	 (data	 not	
shown).	 Since	 YAP65	 relieved	
the	 RUNX2-mediated,	 but	 not	
RUNX2(P409A)-mediated	 repres-
sion	of	the	p21CIP1	promoter,	these	
data	 suggest	 that	 direct	 YAP65	
binding	to	RUNX2	is	necessary	to	




ized	 by	 dysregulation	 of	 normal	
cellular	 growth	 controls.	 Our	
studies	were	designed	to	determine	
the	biological	consequences	of	 the	
interaction	 of	 RUNX2	 with	 the	
transcriptional	 coactivator	 YAP65	
in	 the	 context	 of	 anchorage-	
independent	 growth	 and	 cellular	 transformation.	 YAP65	 interacts	
with	RUNX2	through	the	PPPY	domain	of	RUNX2.	We	show	for	the	
first	time	that	one	physiological	consequence	of	the	RUNX2-YAP65	
interaction	 is	 to	 increase	 cell	 transformation	 since	 NIH3T3	 cells	
overexpressing	RUNX2	and	YAP65	exhibited	a	 synergistic	 increase	
in	growth	in	soft	agar.	Although	RUNX2	is	a	strong	transcriptional	
repressor	of	 the	p21CIP1	promoter,	 the	presence	of	YAP65	 relieved	
this	repression	at	both	the	promoter	and	protein	levels.	Further,	the	
ability	of	YAP65	to	relieve	p21CIP1	repression	depended	on	a	direct	
RUNX2-YAP65	 interaction	 since	 mutation	 of	 the	 PPPY	 YAP65-
binding	 site	 on	 RUNX2	 resulted	 in	 failure	 of	 YAP65	 to	 relieve	
RUNX2	 repression	 of	 the	 p21CIP1	 promoter.	 These	 data	 suggest	
that	 the	 RUNX2	DNA-binding	 factor	 may	 regulate	 repression	 or	
activation	of	 specific	 growth-modulating	genes	 and	promote	onco-
genesis	in	the	presence	of	an	appropriate	transcriptional	coactivator.
GST	 pull-down	 assays	 have	 confirmed	 that	 the	 WW	 domain	
of	 RUNX1	 interacts	 directly	 with	YAP65.26	 Since	 all	members	 of	
the	 RUNX	 family	 contain	 a	 perfectly	 conserved	 10	 amino	 acids	
containing	 the	PY	motif,	RUNX2	was	believed	 to	directly	 interact	
with	 YAP65.	 In	 addition,	 the	 TAZ	 coactivator,	 which	 is	 highly	
similar	 to	 YAP65,	 interacts	 with	 RUNX2.36	 Immunoprecipitation	
assays	verified	the	interaction	between	RUNX2	and	YAP65	(Fig.	2).	
Figure 5. Modulation of RUNX2‑mediated repression of the p21CIP1 promoter by YAP65. (A) Location of RUNX2 
binding sites in the p21CIP1 promoter (sites A–C) in relation to the p53/p73 binding sites (a). The sequences of the 
wild type and mutant p21CIP1 double‑stranded, biotinylated DNA probes are shown (b). DNA precipitation and 
Western blot analyses (b, lanes 1,2 no nuclear lysates) show the ability of RUNX2 to bind the double stranded 
oligonucleotide containing the RUNX consensus binding site (b, lane 3). However, RUNX2 is not able to bind 
the mutant binding sequence (b, lane 4). (c) 293T cells were transfected with Flag‑Tag RUNX2(P409A), clone 2 
(lane 1) or RUNX2(P409A), clone 6 (lane 2). Nuclear lysates from the transfectants were incubated with DNA oligos 
containing a RUNX2 binding site and streptavidin beads were used to precipitate the bound complexes. Western 
blot analysis was performed with the DNA‑precipitated proteins. Both mutant RUNX2 clones maintained the ability 
to bind the p21CIP1 oligonucleotide (lanes 1A, 2A) with no detectable mutant RUNX2 remaining in the superna‑
tant after precipitation (lanes 1B, 2B). (B) NIH3T3 cells were transfected with pTK‑renilla (0.05 mg), WWP‑LUC 
(1.0 mg), and 1.0 mg of control NEO vector (NEO), RUNX2 (R2), or two different clones of RUNX2(P409A), 
clone 2 (cl2) or clone 6 (cl6). Both RUNX2(P409A) clones repressed p21CIP‑promoter luciferase activity. 
*p ≤ 0.002 for P409A_cl2 vs NEO or for RUNX2 vs NEO; ** p ≤ 0.003 for P409A_cl6 vs NEO. (C) NIH3T3 
cells were transfected with pTK‑renilla, WWP‑LUC, a constant amount of RUNX2, NEO control, or P409A clone 
2 DNA (0.25 mg), and increasing amounts of YAP65 (0 mg, 0.1 mg, 0.25 mg, 0.5 mg, 1.0 mg). YAP65 alleviated 
the RUNX2 repression of the p21CIP1 promoter. Results represent a combination of data from three separate experi‑
ments performed in duplicate or triplicate (n = 8). *p ≤ 0.004 for RUNX2 vs. NEO control at 0ug YAP65. YAP65 
was unable to relieve the RUNX2(P409A) repression of the p21CIP1 promoter. **p ≤ 0.004 for RUNX2(P409A) 
vs NEO control at 1.0 mg YAP65. Results represent a combination of data from three separate experiments per‑





















WW	domain	 of	YAP65.26,37	Mutation	 of	 the	 first	 proline	 residue	
to	 alanine	 (P409A)	 resulted	 in	 the	 inability	 of	YAP65	 to	 associate	
with	the	mutated	RUNX2	as	shown	by	immunoprecipitation	assays	
(Fig.	 2)	 and	 failure	 to	 stimulate	 growth	 in	 soft	 agar	 (Fig.	 3).	
As	 expected,	 RUNX2(P409A)	 retained	 the	 ability	 to	 bind	 DNA	
and,	 similar	 to	wild-type	RUNX2,	RUNX2(P409A)	 also	 repressed	
the	 p21CIP1	 promoter	 as	 shown	 using	 transactivation	 assays	
(Fig.	5).	Therefore,	the	point	mutation	in	RUNX2(P409A)	did	not	





RUNX2	 contains	 multiple	 lysine	 residues	 that	 are	 the	 targets	
of	 protein	 acetylation	 and	 ubiquitination.38	The	 E3	 ligases,	 smad	
ubiquitination-related	 factors	 (Smurfs)	 interact	 with	 the	 PPxY	
motif	 of	RUNX2	 through	 their	WW	domains	 leading	 to	RUNX2	
ubiquitination	 and	 degradation	 by	 the	 proteasome	 pathway.39,40	
Since	 YAP65	 interacts	 with	 the	 same	 PPxY	 motif	 on	 RUNX2,	
YAP65	 binding	 could	 block	 ubiquitination	 and	 stabilize	 RUNX2	
levels,	thus	increasing	cell	transformation.	Further	studies	to	address	
whether	any	of	these	mechanisms	are	operative	in	RUNX2-mediated	






YAP65	 is	 cell-dependent.	 However,	 in	 both	 cases	 YAP65	 inhibits	
RUNX2	transcriptional	activity	of	either	the	osteocalcin	or	p21CIP1	
promoter.
We,	 and	others	have	 shown	 that	RUNX2	 represses	 the	p21CIP1	
promoter16,31	 and	 reduces	 expression	 of	 p21CIP1	 protein.16,31	
A	 segment	 of	 DNA	 containing	 the	 consensus	 sequence	 for	 the	
distal	RUNX	binding	site	plus	the	flanking	sequence	in	the	p21CIP1	
promoter	 (site	 A)	 was	 used	 in	 DNA	 precipitation	 assays	 (Fig.	 5).	
The	 role	 of	 the	 other	 two	 RUNX	 binding	 sites	 in	 the	 p21CIP1	
promoter	 (sites	 B	 and	 C)	 is	 not	 known.	 However,	 deletion	 of	
site	 A	 completely	 abrogated	 the	 ability	 of	 RUNX1	 to	 repress	 the	
p21CIP1	promoter.15	We	have	 found	 that	 the	 expression	of	YAP65	
relieved	 the	RUNX2	repression	of	 the	p21CIP1	promoter	 in	a	dose	
dependent	 manner.	 Although	 HA.YAP65	 completely	 relieved	 the	
RUNX2	repression	of	the	p21CIP1	promoter,	no	increased	activation,	
beyond	 initial	 basal	 levels,	 was	 observed	 with	 higher	 doses	 of	
HA.YAP65.	The	 2.4	 kb	 segment	 of	 p21CIP1	 promoter	 contains	 a	
p73	 site	 (Fig.	 5A).	 Therefore,	 we	 considered	 the	 possibility	 that	
YAP65	could	interact	with	endogenous	p73	to	transactivate	p21CIP1	
since	the	WW	domain	of	YAP65	can	also	bind	the	PY	motif	in	p73	
and	 enhance	 p73	 transcriptional	 activity.29	 However,	 increasing	




It	 has	 been	 suggested	 that	 p21CIP1	 acts	 as	 a	 cdk	 inhibitor	 to	
restrain	cell	cycle	progression,	but	it	may	also	function	as	an	assembly	
factor	 for	 cdk/cyclin	 complexes	 to	 promote	 cell	 cycle	 progres-
sion.41-43	 Further,	 p21CIP1	 has	 been	 shown	 in	 a	 variety	 of	 studies	
to	 promote	 cell	 transformation,44-46	 including	 the	 transformation	
observed	 in	mouse	 fibroblasts	 expressing	 the	 Src	 oncoprotein47	 or	
the	 putative	 oncogene	MCT-1.41	 In	 addition,	 several	 reports	 have	
shown	that	p21CIP1	expression	may	contribute	to	tumor	progression	
in	 prostate,48	 ovarian,49	 cervical,50	 breast51	 and	 esophageal52	
carcinomas,	and	brain	tumors53	perhaps	by	promoting	the	synthesis	




growth.	 Recent	 reports	 have	 shown	 that	 p21CIP1	 reduces	
the	effectiveness	of	DNA	damaging	agents	in	HCT116	colorectal	cancer	
cells	by	inhibiting	DNA	damage-induced	apoptotic	events.54	These	








tion	 with	 RUNX2.	 YAP65	 and	 RUNX2	 expression	 reduced	 cell:
cell	contact	inhibition	and	synergistically	enhanced	anchorage-inde-
pendent	 growth	 of	 NIH3T3	 fibroblasts.	 Although	 the	 association	
of	 RUNX2	 and	 YAP65	 on	 the	 p21CIP1	 promoter	may	 contribute	
to	 cellular	 transformation,	 it	 is	 possible	 that	 RUNX2-YAP65	may	
control	 the	 expression	 of	 other	 genes	 that	 regulate	 cellular	 trans-
formation.	 Therefore,	 future	 studies	 using	 this	 model	 of	 tumor	
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